Overview
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Basic Stats
The share price of Epizyme Inc as of August 11, 2022 is $1.47 / share.
The Factor Analysis chart (below right) shows a view of Epizyme Inc from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Epizyme Inc is $3.04. The forecasts range from a low of $1.46 to a high of $6.30. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
| Record Date | Projection Date | High | Low | Median | Average |
|---|---|---|---|---|---|
| 2023-03-27 | 2024-03-27 | 6.30 | 1.46 | 1.53 | 3.04 |
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Epizyme Inc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-06-28 | Cowen & Co. | Outperform | Market Perform | Downgrade |
| 2022-06-27 | Wedbush | Outperform | Neutral | Downgrade |
| 2022-06-03 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-05-12 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-03-02 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-08-10 | Morgan Stanley | Equal-Weight | Underweight | Downgrade |
| 2021-08-10 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-05-07 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2021-05-07 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-04-19 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-03-31 | Credit Suisse | Outperform | Initiate | |
| 2021-02-25 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2020-12-21 | Jefferies | Buy | Hold | Downgrade |
| 2020-11-09 | Morgan Stanley | Overweight | Maintains | |
| 2020-08-05 | Morgan Stanley | Overweight | Maintains | |
| 2020-06-19 | SVB Leerink | Market Perform | Maintains | |
| 2020-06-19 | Morgan Stanley | Overweight | Maintains | |
| 2020-05-05 | Oppenheimer | Perform | Maintains | |
| 2020-04-01 | Oppenheimer | Outperform | Perform | Downgrade |
| 2020-03-04 | Barclays | Overweight | Initiate | |
| 2020-01-24 | Wedbush | Outperform | Maintains | |
| 2020-01-24 | Morgan Stanley | Overweight | Maintains | |
| 2020-01-23 | Citigroup | Buy | Maintains | |
| 2019-12-06 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2019-01-07 | Leerink Swann | Market Perform | Outperform | Upgrade |
| 2018-11-05 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-09-25 | Leerink Swann | Market Perform | Initiate | |
| 2018-07-03 | Leerink Swann | Outperform | Market Perform | Downgrade |
| 2018-04-24 | Wedbush | Outperform | Outperform | Maintains |
| 2018-03-14 | Leerink Swann | Outperform | Outperform | Maintains |
| 2018-01-10 | Morgan Stanley | Overweight | Initiate | |
| 2017-11-02 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2017-11-02 | Leerink Swann | Outperform | Maintains | |
| 2017-09-20 | Jefferies | Buy | Initiate | |
| 2017-04-13 | Oppenheimer | Outperform | Initiate | |
| 2016-04-05 | Citigroup | Buy | Initiate | |
| 2016-03-14 | H.C. Wainwright | Neutral | Buy | Upgrade |
| 2016-03-10 | Leerink Swann | Outperform | Maintains | |
| 2016-03-09 | JMP Securities | Market Outperform | Maintains | |
| 2015-12-22 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2015-08-31 | Leerink Swann | Outperform | Maintains | |
| 2015-07-20 | H.C. Wainwright | Buy | Neutral | Downgrade |
| 2015-07-06 | RBC Capital | Outperform | Initiate | |
| 2015-04-30 | Citigroup | Neutral | Maintains | |
| 2015-03-13 | JMP Securities | Market Outperform | Maintains | |
| 2014-11-07 | Citigroup | Buy | Maintains | |
| 2014-09-12 | Mizuho | Buy | Initiate | |
| 2013-11-15 | Citigroup | Buy | Maintains | |
| 2013-06-27 | Wedbush | Outperform | Initiate | |
| 2013-06-25 | Leerink Swann | Outperform | Initiate | |
| 2013-06-25 | JMP Securities | Outperform | Initiate | |
| 2013-06-25 | Citigroup | Buy | Initiate |
